Clinical Trial: Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naive AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells

U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07236931) titled 'Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naive AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells' on Nov. 14.

Brief Summary: This study aims to evaluate the efficacy and safety of selinexor-based chemotherapy-sparing regimens (including chemotherapy-free or dose-reduced approaches) in optimizing therapeutic strategies for treatment-naive acute myeloid leukemia patients deemed unfit for intensive induction therapy. The investigation will focus on dynamic blast clearance patterns and early toxicity profiles to inform timely treatment adaptat...